Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.36 |
| ▸ | NQO1 | P15559 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.34 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9858819 | 0.83 | ALDH1A1 (0.41) | ALDH1A1KDM4EGAAHSD17B10HIF1A | |
| SCHEMBL11739257 | 0.83 | CYP1A2 (0.43) | ALDH1A1KDM4EGAAHSD17B10HIF1A | |
| SCHEMBL264358 | 0.81 | ALDH1A1 (0.56) | ALDH1A1HSD17B10CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL28256069 | 0.81 | NQO1 (0.42) | ALDH1A1KDM4EGAAHSD17B10HIF1A | |
| SCHEMBL6677010 | 0.80 | ALDH1A1 (0.43) | ALDH1A1KDM4EGAAHSD17B10HIF1A | |
| SCHEMBL22288169 | 0.80 | ALDH1A1 (0.40) | ALDH1A1KDM4EGAAHSD17B10HIF1A | |
| SCHEMBL29114645 | 0.80 | ALDH1A1 (0.39) | ALDH1A1KDM4EGAAHSD17B10HIF1A | |
| SCHEMBL1988094 | 0.80 | UGT2B7 (0.47) | ALDH1A1KDM4EGAAHSD17B10HIF1A | |
| SCHEMBL28005976 | 0.80 | ALDH1A1 (0.45) | ALDH1A1KDM4EGAAHSD17B10HIF1A | |
| SCHEMBL27934859 | 0.80 | ALDH1A1 (0.39) | ALDH1A1KDM4EGAAHSD17B10HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975248-B2 | Combinations of therapeutic agents for treating cancer | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2015-03-10 | — | — | US | disclosed |
| EP-2112154-B1 | Esters in position 20 of camptothecins | SIGMA TAU IND FARMACEUTI (IT) | 2013-07-24 | — | — | EP | disclosed |
| US-8053460-B2 | Chemoosensitizer for dug resistance tumors | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2011-11-08 | — | — | US | disclosed |
| US-20110087034-A1 | Organic Semiconductor Material | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2011-04-14 | — | — | US | disclosed |
| EP-2248818-A1 | ORGANIC SEMICONDUCTOR MATERIAL | Sumitomo Chemical Company, Limited (JP) | 2010-11-10 | — | — | EP | disclosed |
| US-7816386-B2 | Cinnamic, phenylpropiolic and phenylpropanoic acid derivatives useful as anti-tumor agents | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-10-19 | — | — | US | disclosed |
| EP-1511752-B3 | CAMPTOTHECINS WITH A MODIFIED LACTONE RING | SIGMA TAU IND FARMACEUTI (IT) | 2010-03-10 | — | — | EP | disclosed |
| US-20100028338-A1 | Gimatecan (7-t-butoxyiminomethylcamptothecin) and chemotherapeutic agents | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| EP-2112154-A1 | Esters in position 20 of camptothecins | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2009-10-28 | — | — | EP | disclosed |
| EP-1581475-B1 | SYNTHESIS OF (R) AND (S)-AMINOCARNITINE AND DERIVATIVES THEREOF FROM D-AND L-ASPARTIC ACID | SIGMA TAU IND FARMACEUTI (IT) | 2009-09-16 | — | — | EP | disclosed |
| US-20030153783-A1 | Synthesis of (R) and (S)-aminocarnitine, (R) and (S)-4-phosphonium-3-amino-butanoate, (R) and (S) 3,4-diaminobutanoic acid, and their derivatives starting from D- and L-aspartic acid | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. | 2003-08-14 | — | — | US | disclosed |
| US-6589939-B2 | Also useful in treating viral infections; antiprotozoa (plasmodium) activity | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2003-07-08 | — | — | US | disclosed |
| US-6528684-B1 | Blocking amino group, cyclizing to anhydride, decarbonylation lactonation, hydrolysis, dehydroxylation quaternation using trimethyl ammonium halide, converting to internal carboxylic amine salt and deblocking | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2003-03-04 | — | — | US | disclosed |
| EP-1044977-B1 | Camptothecin derivatives having antitumor activity | SIGMA TAU IND FARMACEUTI (IT) | 2002-05-02 | — | — | EP | disclosed |
| EP-1194398-A1 | SYNTHESIS OF (R) AND (S)-AMINOCARNITINE AND THEIR DERIVATIVES STARTING FROM D- AND L-ASPARTIC ACID | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2002-04-10 | — | — | EP | disclosed |
| US-20010008939-A1 | Camptothecin derivatives having antitumor activity | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.. | 2001-07-19 | — | — | US | disclosed |
| US-6242457-B1 | OXIME DERIVATIVES | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2001-06-05 | — | — | US | disclosed |
| WO-2001002341-A1 | SYNTHESIS OF (R) AND (S)-AMINOCARNITINE AND THEIR DERIVATIVES STARTING FROM D- AND L-ASPARTIC ACID | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2001-01-11 | — | — | WO | disclosed |
| EP-1044977-A1 | Camptothecin derivatives having antitumor activity | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2000-10-18 | — | — | EP | disclosed |
| WO-2000053607-A1 | CAMPTOTHECIN DERIVATIVES HAVING ANTITUMOR ACTIVITY | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2000-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100028338-A1 | Gimatecan (7-t-butoxyiminomethylcamptothecin) and chemotherapeutic agents | HDAC6, HDAC1, HDAC8 | ALDH1A1 3549/4885KDM4E 2087/4885GAA 433/4885 |
| US-20030153783-A1 | Synthesis of (R) and (S)-aminocarnitine, (R) and (S)-4-phosphonium-3-amino-butanoate, (R) and (S) 3,4-diaminobutanoic acid, and their derivatives starting from D- and L-aspartic acid | BCAT1, BCAT2, DDC | ALDH1A1 2133/4885KDM4E 1651/4885GAA 3707/4885 |
| US-20010008939-A1 | Camptothecin derivatives having antitumor activity | TOP1, TOP2A, TYMP | ALDH1A1 2202/4885KDM4E 4795/4885GAA 1667/4885 |
| US-20110087034-A1 | Organic Semiconductor Material | OR10J3, TST, OR51E2 | ALDH1A1 137/4885KDM4E 1272/4885GAA 4626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.